OR-GUROBI-OPTIMIZATION
14.11.2022 15:01:59 CET | Business Wire | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the release of Gurobi Optimizer 10.0. This release provides customers with a boost to its already industry-leading speed, the ability to embed machine learning models directly into Gurobi optimization models, and new tools for model development, monitoring, and advanced diagnosis—so users can solve new types of problems, even faster than before.
Performance Improvements and Advanced Solving Techniques
The Gurobi R&D team continues to push the boundaries of performance—resulting in improvements to existing algorithms and the development of several brand-new techniques. As a result, Gurobi Optimizer 10.0 has achieved the following performance improvements since the release of Gurobi Optimizer 9.5:
Type |
Algorithm |
Overall speed-up |
On >100sec models |
LP |
Concurrent |
10% |
25% |
Primal Simplex |
3% |
10% |
|
Dual Simplex |
3% |
10% |
|
MIP |
MILP |
13% |
24% |
Convex MIQP |
57% |
2.4x* |
|
Convex MIQCP |
28% |
88%* |
|
Non-Convex MIQCP |
51% |
2.6x |
|
*MIQP and MIQCP hard model test sets are smaller than for other problem classes. |
|||
“We’ve achieved a more than 75x speedup on MILP since version 1.1. But more importantly, Gurobi 10.0 can now solve even more models easily, including some models that were, until now, intractable,” explained Dr. Tobias Achterberg, Vice President of Research and Development at Gurobi Optimization.
Gurobi 10.0 also includes the following advances in the underlying algorithmic framework:
- New network simplex algorithm – Greatly speeds up solving LPs with network structure.
- New heuristic for QUBO models, which can arise in quantum optimization – Improves Gurobi's ability to quickly find good feasible solutions for quadratic unconstrained Boolean optimization problems.
- Significant performance gains on MIPs that contain machine learning models – Results in a more than 10x improvement on certain models that contain embedded neural networks with ReLU activation functions.
- New optimization-based bound tightening (OBBT) algorithm – Greatly speeds up solving nonconvex MIQCP models.
- Reorganized concurrent LP solver – Improves performance and reduces memory footprint.
Innovative Data Science Integration
With Gurobi Machine Learning—an open-source Python project to embed trained machine learning models directly into Gurobi—data scientists can more easily tap into the power of mathematical optimization.
Specifically, Gurobi Machine Learning allows users to add a trained machine learning model as a constraint to a Gurobi model (e.g., from scikit-learn, TensorFlow/Keras, or PyTorch). Thus, users can estimate a real-world system by training a machine learning model, and then use this machine learning model as a constraint in Gurobi, in order to optimize controls on that system.
“We’re aiming to connect the world of data science with the world of optimization. With Gurobi, you can take your machine learning ‘black box’ that’s generating your predictions and plug it directly into your optimization model—enabling you to connect your forecasting with optimization,” explained Achterberg.
With this release, we're also making it more convenient to integrate gurobipy model building with pandas objects through a new, dedicated open-source package. (Available on GitHub/PyPI in Q4 2022.)
Enterprise Development and Deployment Experience
To make its solver even more accessible and easy to use, the Gurobi team has integrated new tools for model development, monitoring, and advanced diagnosis:
- Significant enhancements to the matrix-friendly API in gurobipy – All matrix-friendly modeling objects now support multiple dimensions, and dimension handling leans consistently on NumPy, including broadcasting.
- New logistic general constraint – Makes it easy to incorporate a constraint in MIP that models the logistic function.
- NuGet package for .NET – Allows .NET users to download Gurobi directly from the NuGet server.
- Memory limit parameter that allows graceful exit – Users can set a memory limit and still get the best solution and resume the optimization after the limit was hit.
- New Compute Server dashboards – The Gurobi Compute Server now includes two new dashboards, enabling users to monitor metrics over time and drill down to the actual activity to better understand the cluster usage and application behavior.
- Expanded platform support – Gurobi 10.0 includes support for Python 3.11 and Linux on ARM 64-bit.
Gurobi introduced its Web License Service (WLS) for Docker and Kubernetes container environments last year, with the release of Gurobi 9.5. With Gurobi 10.0, the team has expanded WLS to support nearly all types of containerized environments. Moreover, customers can now also obtain WLS licenses that allow them to run Gurobi in virtually all deployment scenarios, including containerized environments, virtual machines, and bare-metal machines, across Linux, macOS, and Windows.
“Our customers love our WLS and the flexibility it provides. And now they can dynamically deploy Gurobi software in even more environments,” explained Duke Perrucci, Gurobi’s Chief Operating Officer.
Additionally, starting with Gurobi 10.0, major product releases—and their subsequent minor and technical product releases—will be supported for a term of three years from the initial major product release date. For example, Gurobi version 10.0.0 (released in November 2022) and minor releases between 10.0 and 11.0 will be supported until November 2025.
“This helps create predictability for our customers, so they know exactly how long a version will be supported,” explained Dr. Sonja Mars, Director of Optimization Support at Gurobi Optimization. “We aim to deliver expert technical guidance and support for our customers—and this policy helps eliminate the guesswork. We want our customers to get the help they need, when they need it.”
Dr. Edward Rothberg, Chief Executive Officer and Co-founder of Gurobi Optimization added, “We have the absolute best minds in optimization here at Gurobi. Across every department, you’ll find people who aren’t just smart—they’re also deeply committed to our customers and to providing the best possible experience. I’m proud to be a part of this team.”
To learn more about Gurobi 10.0, please visit gurobi.com/whats-new-gurobi-10-0/.
About Gurobi Optimization
With Gurobi’s decision intelligence technology, you can make optimal business decisions in seconds. From workforce scheduling, portfolio management, and marketing optimization, to supply chain design, and everything in between, Gurobi identifies your optimal solution, out of trillions of possibilities.
As the leader in decision intelligence, Gurobi delivers easy-to-integrate, full-featured software and best-in-class support, with an industry-leading 98% customer satisfaction rating.
Founded in 2008, Gurobi has operations across the Americas, Europe, and Asia. Over 2,500 global customers across 40+ industries run on Gurobi, including SAP, Air France, and the National Football League, as well as half of the Fortune 10 and 70% of top global tech companies. For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005243/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
